Mobia Medical, Inc. IPO - What You Need to Know

Thinking about buying into the Mobia Medical IPO? It is exciting to get in early, but let’s break down what is happening in plain English before you invest your hard-earned money.

1. What does this company actually do?

Mobia Medical is a neuro-tech company tackling a major problem: chronic stroke recovery. Their flagship product, the Vivistim System, is the first FDA-approved device to help stroke survivors regain movement in their arms and hands.

Think of it as a "pacemaker for the brain." It is a small implant that sends gentle pulses to the vagus nerve while the patient does physical therapy. This helps the brain "re-wire" itself to restore movement, even years after a stroke. Since there is no standard treatment for motor recovery after the first few months, Mobia is creating a brand-new medical category. The system includes an implant, a wire, and a wireless transmitter for therapy sessions.

2. How are they performing?

Mobia is growing fast, but they are spending heavily to get there.

• Sales are climbing: In 2025, they brought in $32 million, more than double the $15.6 million they made in 2024. They make this money by selling Vivistim kits to hospitals and surgical centers.
• The "Burn": Despite that growth, they are losing money. They lost $46.5 million in 2025, following a $42.1 million loss in 2024. They spend most of this cash on hiring sales staff, marketing, and running clinical trials.
• The IPO Cash: They expect to raise about $134.5 million. This is a lifeline. Without this cash, the company says there is "substantial doubt" they can stay in business, as their current funds won't last another 12 months.

3. What’s the market opportunity?

There are roughly 10 million stroke survivors in the U.S. Mobia believes 1 million of these people are candidates for their device, representing a $30 billion market. Because their trials show success even in patients who had strokes decades ago, their potential user base is huge. They are currently focusing on U.S. stroke rehab centers and neuro-surgical practices.

4. What are the main risks?

• Survival Risk: Auditors have warned that the company’s history of losses puts its future in jeopardy. They need this IPO money to survive. If they fail to raise these funds or become profitable, they may have to shut down.
• Insurance Coverage: This is the biggest hurdle. Many insurance companies still view this therapy as "experimental." If they don't get broader coverage, patients will struggle to afford the high out-of-pocket costs.
• Growing Pains: Rapid growth is difficult. They have scaled their sales team to 83 people, and managing this growth is a major challenge. If they cannot train their team or handle supply chain issues, revenue will suffer.
• Financial Reporting: They admitted to a "material weakness" in their financial reporting due to a lack of accounting staff. This means their systems for tracking money are not as strong as a typical public company's, which is a red flag for accuracy.

5. The Details

• Ticker Symbol: MOBI (Nasdaq)
• Price: $15.00 per share
• Date: Expected around May 11, 2026.

Final Thoughts for Potential Investors

Investing in a company like Mobia is a "high-risk, high-reward" scenario. You are betting that their technology will become the standard of care for stroke recovery and that they can secure the insurance coverage needed to make the product accessible.

Before you decide, ask yourself: Am I comfortable with a company that is currently reliant on this IPO just to keep the lights on? If the answer is no, you might want to watch from the sidelines until they prove they can turn a profit.

A quick reminder: I am an AI, not a financial advisor. IPOs are volatile—the price can swing wildly. Never invest money you cannot afford to lose, and check the official "Prospectus" on the SEC website for the full details.